Related trials
TRIANA, 2009 - primary ballon angioplasty vs tenecteplase
DEBATER (SES vs BMS), 2009 - sirolimus eluting stent vs bare-metal stent
NORDISTEMI, 2009 - thrombolysis + angioplasty vs immediate thrombolysis
Juwana, 2009 - sirolimus eluting stent vs paclitaxel eluting stent
ZEST AMI (vs PES), 2009 - zotarolimus eluting stent vs paclitaxel eluting stent
PASEO, 2009 - drug-eluting stents vs bare-metal stent
ZEST AMI (vs SES), 2009 - zotarolimus eluting stent vs sirolimus eluting stent
CARESS, 2008 - thrombolysis + angioplasty vs immediate thrombolysis
HORIZONS-AMI Stent, 2008 - paclitaxel eluting stent vs bare-metal stent
MISSION, 2008 - sirolimus eluting stent vs bare-metal stent
DEDICATION, 2008 - drug-eluting stents vs bare-metal stent
D�az de la Llera, 2007 - sirolimus eluting stent vs bare-metal stent
SESAMI, 2007 - sirolimus eluting stent vs bare-metal stent
PROSIT, 2006 - sirolimus eluting stent vs paclitaxel eluting stent
HAAMU-STENT, 2006 - paclitaxel eluting stent vs bare-metal stent
PASSION, 2006 - paclitaxel eluting stent vs bare-metal stent
WEST, 2006 - systematic PCI (+stent) vs no systematic PCI
TYPHOON, 2006 - sirolimus eluting stent vs bare-metal stent
ZWOLLE 6, 2005 - primary stenting vs balloon angioplasty
CAPITAL AMI, 2005 - systematic PCI (+stent) vs no systematic PCI
senior PAMI, 2005 - primary PCI vs Thrombolysis
CAPITAL AMI, 2005 - thrombolysis + angioplasty vs immediate thrombolysis
Di Lorenzo et al., 2005 - sirolimus eluting stent vs paclitaxel eluting stent
GRACIA-1, 2004 - systematic PCI (+stent) vs no systematic PCI
MERLIN (Sutton), 2004 - immediate systematic ballon angioplastyte vs no immediate angioplasty
See also:
All acute myocardial infarction clinical trials
All clinical trials of PCI
All clinical trials of primary PCI
|
|
Treatments
Studied treatment |
primary percutaneous coronary intervention
|
Control treatment |
intravenous thrombolytic therapy
|
Patients
Patients |
elderly (age >= 70 years) patients with acute myocardial infarction |
Exclusion criteria |
systolic blood pressure >180 mm Hg; diastolic blood pressure >100 mm Hg; warfarin |
Method and design
Randomized effectives |
252 / 229 (studied vs. control) |
Design |
Parallel groups |
Blinding |
Open |
Follow-up duration |
30 days |
Primary endpoint |
death or disabling stroke |
Results
Endpoint
Studied treat. n/N
Control treat. n/N
Graph
RR [95% CI]
stroke (fatal and non fatal)
2 / 252
5 / 229
0,36 [0,07;1,86]
In-hospital death
25 / 252
30 / 229
0,76 [0,46;1,25]
0
2
1.0
Relative risks
|
Endpoint |
Events (%) |
Relative Risk |
95% CI |
Endpoint definition in the trial |
Ref |
Studied treat. |
Control treat. |
In-hospital death
|
25 / 252 (9,9%) |
30 / 229 (13,1%) |
0,76 |
[0,46;1,25] |
at 30 days |
|
stroke (fatal and non fatal)
|
2 / 252 (0,8%) |
5 / 229 (2,2%) |
0,36 |
[0,07;1,86] |
disabling at 30 days |
|
The primary endpoint (if exists) appears in blod characters
|
Reference(s) used for data extraction:
|
Endpoint |
studied treat. |
control treat. |
mean diff |
Absolute risk reduction
|
Endpoint |
Events rate |
Absolute risk reduction (ARR) |
Studied treat. |
Control treat. |
In-hospital death |
9,92% |
13,10% |
-31,8‰
|
stroke (fatal and non fatal) |
7,94‰ |
2,18% |
-13,9‰
|
Meta-analysis of all similar trials:
myocardial revascularization in acute myocardial infarction for Elderly patients
myocardial revascularization in acute myocardial infarction for all type of patients
PCI in acute myocardial infarction for all type of patients
PCI in acute myocardial infarction for Elderly patients
Reference(s)
|